Abbott Laboratories stock drifts into earnings after Canada widens Libre 3 Plus coverage
Abbott said its FreeStyle Libre 3 Plus glucose sensor is now publicly funded in every Canadian province. Shares closed down 0.2% at $125.92 Friday, trailing the S&P 500. Analysts adjusted price targets ahead of Abbott’s Jan. 22 earnings report. The company’s $23 billion Exact Sciences deal is expected to close in Q2 2026.